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Background: To evaluate efficacy and toxicity of hypofractionated intensity-modulated simultaneous integrated
boost (IMRT-SIB) and image-guided (IGRT) radiotherapy in the treatment of high-risk prostate cancer patients.
Methods: Eighty-two patients with high-risk prostate cancer were analysed. An IMRT treatment was planned
delivering 68.75 Gy to the prostate, 55 Gy to the seminal vesicles and positive nodes and 45 Gy to the pelvis in 25
fractions. The first 59 patients received 4 weekly fractions whereas the last 23 patients received 5 weekly fractions.
All patients were submitted to hormonal therapy.
Results: The median follow-up was 31 months. Acute grade 1–2 gastrointestinal (GI) toxicity rates were 13.4%.
Grade 1–2 and grade 3 genitourinary (GU) toxicity rates were 22% and 1.2%, respectively.
Grade 1 and 2 GI late toxicity rates were 1.2%. No grade ≥3 toxicity was recorded. Grade 1 GU late toxicity rate was
2.4%. No grade ≥2 toxicity was recorded.
No significant difference was calculated in terms of acute and late toxicity between the group treated 4 or 5 times
weekly.
The actuarial 3-years Overall survival and Freedom from biochemical failure were 98.6% and 91.3%, respectively.
Conclusions: The present study demonstrated that hypofractionated IGRT-IMRT-SIB in patients with high-risk
prostate cancer is efficient with acceptable toxicity profile. Outcome in terms of survival are promising, but longer
follow-up is needed.
Keywords: Hypofractionation, High risk prostate cancer, IMRT-SIBBackground
High-risk prostate cancer requires a multimodality ap-
proach therapy. One of the standard curative treatments
is the definitive radiation therapy (RT) associated with
androgen deprivation therapy (ADT) [1,2]. Several random-
ized trials have shown excellent long-term biochemical
outcome with higher radiation doses [3].
Recent literature suggests that adenocarcinoma of the
prostate gland is different from many other malignancies,
with an average a/b ratio about 1.5 Gy (range, 0.8–2.2).* Correspondence: mauval1@libero.it
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unless otherwise stated.The a/b ratio for late rectal radiation effects is generally
calculated between 3 and 4 Gy [4-6]. The rationale of
hypofractionated radiotherapy (HFRT) consists in the
lower a/b ratio of prostate cancer compared to adjacent
organs at risk (OAR). Higher dose per fraction can im-
prove local control increasing the biological effective
dose (BED) to the tumor without increasing the risk for
late effects. Moreover, using reduced total dose can be
unsafe in high-risk patients with Gleason score higher
than 7, becauce α/β ratio could not be so low [7].
Hypofractionated radiotherapy can be carried out safety
after the development of image-guided radiotherapy (IGRT)
and intensity-modulated radiotherapy (IMRT). IMRT hasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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calation in localized prostate cancer, and better conformed
radiotherapy to pelvic lymph nodes for higher-risk pros-
tate cancer. Although, the pelvic lymph node irradiation is
still controversial, randomized data have supported its use
[8]. In addition, most of the randomized trials have shown
that pelvic irradiation combined long-term ADT had a
survival benefit [1,2].
In 2009, according to these postulations, we started a
prospective study at our institution using a hypofrac-
tionated schedule with SIB-IMRT-IGRT technique
including patients with high-risk prostate cancer. The




Between November 2009 and September 2013, 105 pa-
tients with biopsy proven, high-risk prostate cancer
were treated with hypofractionated radiation therapy
with SIB-IMRT-IGRT. Under a S. Andrea Hospital IRB-
approved protocol the data were prospectively collected
and retrospectively analyzed to evaluate the efficacy and
the tolerance. Written inform consent was obtained by all
patients.
A minimum follow up time of 12 months was required
as inclusion criteria. For this reason, 82 patients were
selected for the statistical analysis in the present study.
Median age at diagnosis was 74 years (range 58–88
years). All patients presented cT3/4 N0/N1 M0 clinical
stage and/or a Gleason score of ≥ 8 and/or a pre-treatment
prostate-specific antigen (PSA) serum level ≥ 20 ng/ml.
Pre-treatment evaluation included: a complete physical
examination, PSA level, complete blood counts and
standard biochemistry tests, bone scan, total body
computed tomography (CT) with contrast medium and
prostate magnetic resonance image (MRI) with diffusion
and perfusion sequences. Three patients (3,7%) presenting
with clinical positive node (external iliac station) were
submitted to PET scan with choline to confirm nodal
involvement.
Median of PSA value at diagnosis was 9.87 ng/ml (range
3–89.7 ng/ml). Patient characteristics are summarized in
Table 1. Written informed consent was provided by all
patients.
Treatment
All patients underwent CT planning (2.5 mm slice
thickness) in the supine position with feet rests for the
implementation of treatment planning. The preparation
for CT scan comprises the administration to a mini
enema for rectal emptying and then patients were in-
vited to next urination. Also, they were requested to
drink 500 ml of water half an hour before the start ofthe procedure to fulfil the bladder. Planning CT was
fused with MRI images (diffusion ADC map, perfusion
series and axial high resolution T2-w) using point-to-point
matching to help clinical target volume (CTV) delineation.
Wide description of the treatment patterns was previ-
ously reported [9].
Eclipse inverse planning system (Varian) was used to
calculate IMRT plans with simultaneous integrated boost.
The PTV1 (prostate) was planned to receive 68.75 Gy
(2.75 Gy per fraction). The PTV2 (seminal vesicles) and
the PTV4 (positive nodes) were planned to receive 55 Gy
(2.2 Gy per fraction) and the PTV3 (pelvis) was planned
to receive 45 Gy (1.8 Gy per fraction) in 25 fractions. For
patients with cT3b, the PTV2 received the same dose as
the PTV1. The first 59 patients (72%) received 4 weekly
fractions, with overall treatment time of 43 days. The last
23 patients (28%) received 5 weekly fractions, with overall
treatment time of 33 days.
Prior to each treatment, patients underwent a Kilo-
voltage cone-beam CT that was compared with the
planning CT to verify the correct position. The patients’
position was adjusted with an initial automatic bone align-
ment, followed by a soft tissue alignment using the
prostate-rectum interface.
Figure 1 Freedom From Biochemical Failure (FFBF).
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as follows: for the rectum V52Gy < 35% and V61Gy <
25%; for the bladder V45Gy < 50%; for the femoral head
V50Gy < 10%; for peritoneal cavity V54Gy < 5%.
The Normalized Total Dose (NTD) was 82,5 Gy assum-
ing an α/β of 1,5 for the tumour with an iso-effective late
complication total dose of 78 Gy delivered in 39 fractions
considering an α/β of 3 for rectal late adverse effects.
All patients were submitted to neoadjuvant (starting
3 months before radiation therapy), concomitant and
subsequent adjuvant ADT for other 2–3 years using a
luteinizing hormone-releasing hormone (LHRH) analo-
gous plus anti-androgen (bicalutamide 50 mg).
From the start of radiation therapy, all patients were
advised to follow a low-fibre and low-fat diet and to as-
sume a cranberry based integrator and lactic ferment
once daily.
Follow up
Acute toxicities were recorded using the RTOG/EORTC
scale [10] weekly during treatment, at 1 month, at 3 months
after treatment completion. All patients underwent weekly
clinical evaluation and routine blood examinations during
RT. Follow-up was performed every three months for the
first two years and every six months up to five years and
annually afterwards. Performance status, treatment-related
adverse effects, blood count, liver and renal function tests,
PSA were assessed at follow-up.
Statistical analysis
The biochemical failure was defined as the PSA
nadir +2 ng/mL according to Phoenix criteria [11].
Overall survival (OS) and disease free survival (DFS) were
calculated using the Kaplan–Meier method. The chi-
square test was performed to compare 4 times weekly and
5 times weekly treatment-related toxicities between these
two groups. Statistical analyses were performed using
SPSS statistical software package version 13.0 (SPSS, Inc.,
Chicago, IL). A p value lower than 0.05 was considered as
statistically significant.
Results
The overall median follow-up was 31 months (range
12–58 months). The median follow-up for patients
treated 4 times weekly was 40 months (range 13–58
months), whereas for patients treated 5 times weekly
was 23,5 months (range 12–31 months).
The median PSA value before radiotherapy was
0,64 ng/ml (range 0.01-12,7 ng/ml), at the first follow-up
was 0.08 ng/ml (range 0–4,95 ng/ml) and at the last
follow-up was 0.06 ng/ml (range 0–2,9 ng/ml).
The actuarial 3-years overall survival (OS) was 98,6%.
There was one death at the time of the statistical analysis.
The patient died after 13 months from RT completion forcardio-pulmonary disorder and he also presented lumbar-
aortic nodal disease progression. The actuarial 3-years
freedom from biochemical failure (FFBF) was 91,3%
(Figure 1). Three patients developed biochemical failure
due to systemic progression: 2 patients had bone metas-
tasis and 1 patient had lumbar-aortic nodes metastasis.
None of those patients presented loco-regional relapse.Acute toxicities
Toxicities occurred as follows during treatment: grade 1
and grade 2 gastrointestinal (GI) toxicity in 5/82 (6.1%)
and 6/82 patients (7.3%), respectively; grade 1, 2 and 3
genitourinary (GU) toxicity in15/83 (18.3%), 3/82 (3.7%)
and 1/82 patients (1.2%), respectively.
At one month after treatment completion we observed
grade 1 and 2 GI toxicities in 4/82 (4.9%) and in 1/82
patients (1.2%), respectively. Grade 1 and 2 GU toxicities
were experienced by12/82 (14.6%) and 2/82 (2.4%) patients,
respectively.
At 3 months after radiation treatment grade 1 GI toxicity
was observed in 4/82 patients (4.9%). Grade 1 GU toxicity
was observed in 8/82 patients (9,8%). No grade ≥ 2 GU and
GI toxicities were recorded.
No statistically significant difference was calculated
between the two groups treated 4 and 5 times weekly,
respectively during the treatment, at 1 and 3 from the
end of therapy. Data are summarized in Table 2.Late toxicities
At 6 months from the end of therapy, 2 patients (2.4%)
presented grade 1 GI toxicity and 6 patients (7.3%) pre-
sented grade 1 GU toxicity. No grade ≥ 2 toxicities were
recorded.
Table 2 Comparison of acute GI and GU toxicities in the 4 W group vs. 5Wgroup
Acute toxicity GI GU
4 W 5 W
p value*
4 W 5 W
p value*
n. % n. % n. % n. %
during RT
G1 3/59 5.1 2/23 8.7 0.960 11/59 18,6 4/23 17.4 0.509
≥ G2 4/59 6.8 2/23 8,7 2/59 3.4 2/23 8.7
1 months FU
G1 2/59 3.4 2/23 8.7 0.291 5/59 8.5 7/23 30,4 0.134
≥ G2 0 0 1/23 4,3 1/59 1.7 1/23 4.3
3 months FU
G1 3/59 5,1 1/23 4,3 0,692 4/59 6,8 4/23 17,4 0,320
≥ G2 0 0 0 0 0 0 0 0
6 months FU
G1 1/59 1,7 1/23 4,3 0,632 4/59 6,8 2/23 8,7 0,965
≥ G2 0 0 0 0 0 0 0 0
Last FU
G1 1/59 1,7 0 0 0,582 1/59 1,7 1/23 4,3 0,642
≥ G2 0 0 0 0 0 0 0 0
*Chi-square test.
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were observed in 1 patient (1.2%) and 2 patients (2.4%),
respectively. Only 1 patient (1.2%) developed grade 2 GI
toxicity No grade ≥ 3 toxicities were recorded.
No statistically significant difference was recorded be-
tween two groups treated 4 and 5 times weekly, respect-
ively. Data are summarized in Table 2.
Discussion
The lower a/b ratio of prostate cancer compared to the
adjacent OAR predicts for the sparing of normal tissues
when hypofractionated RT is carried out [12]. In
addition, IMRT and daily image guidance have been
shown to improve biochemical disease free survival
(bDFS) and reduce toxicity [13]. The results of the
present prospective trial have shown that a concomitant
SIB-IMRT- IGRT and long-term ADT are safe and well
tolerated with low rates of toxicity.
Moreover, we reported low rates of acute toxicity dur-
ing the treatment with grade 1 and grade 2 GI toxicity
of 6.1% and 7.3%, respectively, and grade 1, 2 and 3 GU
toxicity of 18.3%, 3.7% and 1.2%, respectively. At 3 months
after radiation treatment only 4.9% presented grade 1 GI
toxicity and 9.8% presented grade 1 GU toxicity. In the
current study, we found that the overall treatment time (4
or 5 times weekly) had no impact on acute toxicity rates.
The present study reports outcome regarding bio-
chemical control and late toxicity after a median
follow-up of 31 months. The actuarial 3-years OS was
98.6%. The actuarial 3-years DFS was 91.3% (3 patientsdeveloped biochemical failure due to systemic progres-
sion: 2 patients had bone metastasis and 1 patient had
lumbar-aortic nodes metastasis). None of those patients
presented loco-regional relapse.
In the literature, there are several randomized con-
trolled trials with mature follow-up addressing moderate
hypofractionated radiotherapy in clinically localized pros-
tate cancer. Arcangeli et al. [14] reported the Regina Elena
study, which randomized 168 patients to 80 Gy in 2-Gy
fractions over 8 weeks versus 62 Gy in 3.1-Gy fractions
over 4 weeks. All patients received 9 months of neoadju-
vant, concurrent, and adjuvant androgen deprivation ther-
apy. They demonstrated superior 3-year freedom from
biochemical failure in the hypofractionated arm (FFBF
87% vs. 79%) after a median follow-up time of 3 years. In
a recently update of the previous study, no significant
difference was found in terms of FFBF, overall survival,
or cause-specific survival between treatment arms, after
a median follow-up of 70 months; there were also no
difference in late toxicity [15]. The Fox Chase trial [16]
randomized 303 men with intermediate- and high-risk
prostate cancer to 76 Gy in 2-Gy fractions over 7.5 weeks
versus 70.2 Gy in 2.7-Gy fractions over approximately
5 weeks, using IMRT. Median follow-up was 68.4 months.
The 5-year rates of biochemical and/or clinical disease
failure (BCDF) were 21.4% (95% CI, 14.8% to 28.7%) for
conventional IMRT and 23.3% (95% CI, 16.4% to 31.0%)
for hypofractionated IMRT. There were no statistically
significant difference in late toxicity between the arms;
however, in subgroup analysis, patients with compromised
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urinary function after hypofractionated IMRT. The MD
Anderson [17] randomized 204 men to 75.6 Gy in 1.8-Gy
fractions over 8.5 weeks versus 72 Gy in 2.4-Gy fractions
over 6 weeks. After a median follow-up of 4.7 years, no in-
tergroup difference in 5-year FFBF (hypofractionated vs.
conventional, 96% vs. 92%) has been demonstrated. There
was no significant difference in toxicity, although the
hypofractionated arm trended toward worse GI toxicity.
Three large, multi-institutional, phase III non-inferiority
studies from the MRC, RTOG, and OCOG would provide
better evidence on moderate hypofractionation over the
next few years.
Limited data from prospective studies reported late
toxicity dose-escalation with hypofractionated RT on
prostate cancer patients after longer follow-up. These
studies treated the prostate, the seminal vesicles, with or
without the pelvic lymph nodes.
Kupelian et al. [18] reported 3.1% of grade 2, 1.3% of
grade 3, and 0.1% of grade 4 late toxicity rates after a
median 45 months of follow-up in 770 patients treated
with IMRT hypofractionated schedule of 70 Gy/2.5 Gy
in 28 fractions to the prostate, including or not seminal
vesicles. In particular, the actuarial 5 years rates of
grade ≥ 2 rectal late toxicity was 6% and grade ≥ 2 late
urinary toxicity at 5 years was 7%. However, none of
those patients received whole pelvic RT, and only 60%
had adjuvant androgen deprivation. The role of elective
radiotherapy on the pelvic nodal regions in clinically
node-negative patients remains controversial [19,20]. The
RTOG 9413 [21] trial is a four-arm study of whole-pelvis
RT versus prostate-only RT associated with hormonal
therapy. Patients who received whole-pelvis RT +ADT
experienced grade ≥ 2 late GI and GU toxicity at 5 years of
15.2% and 14.9%, respectively. In our study, the rates of
moderate and severe toxicity were lower compared to the
previous studies.
Intensity-modulated radiation therapy is emerging as
an important technique for more conformal targets of pel-
vic lymph nodes for higher-risk prostate cancer treatment
[10]. Limited clinical data exist on this topic. The current
data suggest a reduced toxicity profile compared to con-
ventional and 3D whole pelvic techniques [22,23]. In a
study by Zelefsky et al. [24], the 3-year actuarial incidence
of late Grade ≥ 2 GI toxicity in patients treated up to
81 Gy with IMRT was 2% compared with 14% in those
treated with 3D-CRT and the same dose. The 3-year
bNED rate was similar in patients treated with both tech-
niques and varied from 92% for favourable and 81% for
unfavourable risk groups. McCammon et al. [25] retro-
spectively analysed patients underwent pelvic IMRT
(50.4 Gy at 1.8 Gy/fraction) and concomitant boost
(70 Gy at 2.5 Gy/fraction) + ADT. Late Grade 2, grade 3
and grade 4 GI toxicities (proctitis) were observed in 6.7%,3.3%, and 3.3%, respectively, after 24 months of median
follow-up. Late grade 2 GU toxicity (urinary frequency/ur-
gency) was observed in 10% of the patients; no grade ≥ 3
was reported.
In the present study the overall median follow up was
31 months. At 6 months after the end of RT 2.4% of the
patients presented grade 1 GI toxicity and 7.3% grade 1
GU toxicity. No grade ≥ 2 toxicity was recorded. At last
follow-up 1.2% of the patients presented grade 1 GI tox-
icity, 1.2% of the patients had grade 2 GI toxicity, and
2.4% of the patients had grade with 1 GU toxicity. No
grade ≥ 3 toxicity was recorded. No significant difference
was recorded between the two groups treated 4 times
weekly and 5 times weekly. Compared to our study,
Quon et al. [26] reported higher rates of acute and late
toxicities in patients with high-risk prostate cancer
treated using IMRT-SIB without IGRT and a total dose
of 45 Gy (1.8 Gy/fraction) to the pelvic lymph nodes +
concomitant boost of 22.5 Gy (2.7 Gy/fraction) to the
prostate. A recent study by Zelefsky et al. [27] reported
improved biochemical relapse-free survival in patients
treated with daily IGRT compared to patients treated
without IGRT. The lower toxicity rates achieved in our
study are likely a result of the advantage of IMRT com-
bined to IGRT.
In our study, we treated 59 patients with four times
weekly radiotherapy considering the hypothesis of
Fowler et al. [28] to maintain BED10 value ≤ 60 Gy.
This value was calculated using the time-adjusted BED
formula BED ¼ nd 1 ¼ dα=β
 
− loge2αTp T−Tkð Þ.
Based on simple linear quadratic (LQ) model including
cell proliferation [29]. Specifically, the overall treatment
time was represented by T, with the first day designated
Day 0. The parameters were selected with a comprehen-
sive review of clinical results from several dozen published
schedules used for head and neck cancer treatment [30].
They included α/β = 10 Gy; α = 0.35 Gy−1; an onset time
for repopulation in human oral mucosa of Tk = 7 days
[31]; and an average doubling time of Tp = 2.5 days there-
after. Although this formula is likely simple containing
only two repopulation rates, zero and Tp, it has served
well in comparing tumor BEDs in the head and neck
schedules studied [5].
The purpose of this schedule is to moderately reduce
the overall treatment time, in order to maintain acceptable
acute toxicity rates. Based on the low rate of toxicity
reported in the first 59 patients we decided to reduce the
total treatment time up to 33 days and, then, the last 23
patients received five fractions per week, with no calcu-
lated difference in terms of observed toxicity rates be-
tween the two groups on the statistical analysis. Regard to
the postulation of Fowler the reported low rate of toxicity
also in patients treated in 33 days may be explained by the
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(5 mm) from CTV to PTV. Our study also presented
limits as the relatively short follow-up time.
Conclusions
Our study demonstrated that hypofractionated radio-
therapy using modern technique is efficient and safe.
Good outcome in terms of survival and low toxicity
rates were observed. The reduction of overall treatment
time does no increase toxicity rates. Longer follow-up is
necessary to confirm these data. Further studies with
longer follow-up are needed to better define outcomes
and late toxicity rates after hypofractionated radiotherapy
in high-risk prostate cancer patients.
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